Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
$34.75
+4.6%
$39.81
$25.43
$44.16
$4.67B1.432.15 million shs3.44 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.40
+0.6%
$26.96
$25.20
$40.37
$143.83B0.6134.12 million shs46.53 million shs
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
+4.57%-8.70%-20.43%+3.27%-5.83%
Pfizer Inc. stock logo
PFE
Pfizer
+0.48%-2.35%-8.61%-7.61%-34.30%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
4.8633 of 5 stars
4.44.02.50.03.11.72.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9759 of 5 stars
3.23.04.24.83.01.73.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
2.71
Moderate Buy$46.4333.61% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.38
Hold$36.3343.04% Upside

Current Analyst Ratings

Latest HOG and PFE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$50.00 ➝ $45.00
4/23/2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$50.00 ➝ $50.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/11/2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$42.00 ➝ $49.00
4/3/2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$45.00 ➝ $50.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/22/2024
Pfizer Inc. stock logo
PFE
Pfizer
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
3/14/2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$50.00 ➝ $55.00
3/5/2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$42.00
3/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
2/27/2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$36.00 ➝ $37.00
(Data available from 4/27/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
$5.84B0.80$7.22 per share4.81$24.80 per share1.40
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.46$2.99 per share8.49$15.81 per share1.61

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
$706.59M$4.507.727.192.1611.03%19.48%5.21%7/25/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3670.569.171.143.62%10.88%4.91%5/1/2024 (Confirmed)

Latest HOG and PFE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/25/2024Q1 2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
$1.48$1.72+$0.24$1.72$1.42 billion$1.48 billion    
2/8/2024Q4 2023
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
$0.04$0.18+$0.14$0.18$875.29 million$791.65 million    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
$0.691.99%+14.47%15.33%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.61%+2.57%466.67%15 Years

Latest HOG and PFE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/24/2024
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.426.4%5/9/20245/10/20246/14/2024
2/16/2024
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
quarterly$0.17251.82%3/1/20243/4/20243/20/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
1.50
1.54
1.25
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
85.10%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
0.87%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Harley-Davidson, Inc. stock logo
HOG
Harley-Davidson
6,400134.52 million133.36 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable

HOG and PFE Headlines

SourceHeadline
Citizens Financial Group Inc. RI Has $4.20 Million Holdings in Pfizer Inc. (NYSE:PFE)Citizens Financial Group Inc. RI Has $4.20 Million Holdings in Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 27 at 11:51 AM
3 Dividend Stocks to Buy and Hold for the Next Decade3 Dividend Stocks to Buy and Hold for the Next Decade
fool.com - April 27 at 7:15 AM
7 Dividend Stocks to Buy Now for Steady Returns in Any Market7 Dividend Stocks to Buy Now for Steady Returns in Any Market
investorplace.com - April 27 at 6:00 AM
Pfizer’s First Gene Therapy Gets Approval for Clotting DisorderPfizer’s First Gene Therapy Gets Approval for Clotting Disorder
bloomberg.com - April 26 at 10:34 PM
Pfizer (NYSE:PFE) Notches Up on New FDA ApprovalPfizer (NYSE:PFE) Notches Up on New FDA Approval
msn.com - April 26 at 10:34 PM
Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)Stanley Laman Group Ltd. Buys 44,722 Shares of Pfizer Inc. (NYSE:PFE)
marketbeat.com - April 26 at 9:14 PM
Pfizer (NYSE:PFE) Stock Price Up 0.3%Pfizer (NYSE:PFE) Stock Price Up 0.3%
marketbeat.com - April 26 at 5:58 PM
What Factors Will Drive Pfizers Q1 Performance?What Factors Will Drive Pfizer's Q1 Performance?
forbes.com - April 26 at 5:34 PM
Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, UniqurePfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure
finance.yahoo.com - April 26 at 5:34 PM
FDA Green Lights Pfizers Gene Therapy For Rare Bleeding Disorder HemophiliaFDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
finance.yahoo.com - April 26 at 5:34 PM
Pfizer (NYSE:PFE) Sets New 52-Week Low at $25.20Pfizer (NYSE:PFE) Sets New 52-Week Low at $25.20
marketbeat.com - April 26 at 2:35 PM
GSK sues Pfizer and BioNTech over mRNA billionsGSK sues Pfizer and BioNTech over mRNA billions
thepharmaletter.com - April 26 at 12:33 PM
Pfizer Gains as Gene Therapy Wins FDA NodPfizer Gains as Gene Therapy Wins FDA Nod
baystreet.ca - April 26 at 12:33 PM
FDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia BFDA approves Pfizer’s gene therapy Beqvez for adults with hemophilia B
thepharmaletter.com - April 26 at 12:33 PM
Gear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key MetricsGear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
zacks.com - April 26 at 10:21 AM
Pfizer Receives FDA Approval for Bleeding Disorder TreatmentPfizer Receives FDA Approval for Bleeding Disorder Treatment
barrons.com - April 26 at 9:35 AM
Want $2,000 in Annual Dividends? Invest $30,000 in These 3 StocksWant $2,000 in Annual Dividends? Invest $30,000 in These 3 Stocks
fool.com - April 26 at 7:45 AM
Pfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia BPfizer Gets FDA OK For Beqvez Gene Therapy for Hemophilia B
marketwatch.com - April 26 at 7:33 AM
Pfizers Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia BPfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B
markets.businessinsider.com - April 26 at 7:33 AM
US FDA approves Pfizers gene therapy for rare bleeding disorderUS FDA approves Pfizer's gene therapy for rare bleeding disorder
reuters.com - April 26 at 7:33 AM
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BU.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
finance.yahoo.com - April 26 at 7:33 AM
Pfizer Now Rivals The Worlds Most Expensive Medicine After FDA Approves Gene TherapyPfizer Now Rivals The World's Most Expensive Medicine After FDA Approves Gene Therapy
finance.yahoo.com - April 26 at 7:33 AM
UPDATE 2-US FDA approves Pfizers gene therapy for rare bleeding disorderUPDATE 2-US FDA approves Pfizer's gene therapy for rare bleeding disorder
finance.yahoo.com - April 26 at 7:33 AM
FDA approves Pfizers first gene therapy for rare inherited bleeding disorderFDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
cnbc.com - April 26 at 7:02 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Harley-Davidson logo

Harley-Davidson

NYSE:HOG
Harley-Davidson, Inc. manufactures and sells motorcycles in the United States and internationally. The company operates in three segments: Harley-Davidson Motor Company, LiveWire, and Harley-Davidson Financial Services. The Harley-Davidson Motor Company segment designs, manufactures, and sells motorcycles, including cruiser, trike, touring, standard, sportbike, adventure, and dual sport, as well as motorcycle parts, accessories, and apparel, as well as licenses its trademarks and related services. This segment sells its products to retail customers through a network of independent dealers, as well as e-commerce channels. The LiveWire segment sells electric motorcycles, balance bikes for kids, parts and accessories, apparel, and related parts and services. The Harley-Davidson Financial Services segment provides wholesale financing services, such as floorplan and open account financing of motorcycles, and parts and accessories; and retail financing services, such as installment lending for the purchase of new and used Harley-Davidson motorcycles, as well as point-of-sale insurance and voluntary protection products. This segment also licenses third-party financial institutions that issue credit cards bearing the Harley-Davidson brand. Harley-Davidson, Inc. was founded in 1903 and is based in Milwaukee, Wisconsin.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.